The influence of metronidazole (MET) resistance on the efficacy of two triple therapy regimens with ranitidine bismuth citrate (RBC) for H-pylori (Hp) infection

被引：0
|
作者：
Van der Wouden, EJ
Thijs, JC
van Zwet, AA
Kooy, A
Kleibeuker, JH
机构：
[1] Univ Groningen Hosp, Groningen, Netherlands
[2] Bethesda Hosp, Hoogeven, Netherlands
来源：
GUT | 1998年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A86 / A86
页数：1
相关论文
共 50 条
  • [1] Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for H-pylori (Hp) infection.
    van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    GASTROENTEROLOGY, 1998, 114 (04) : A323 - A323
  • [2] The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection
    Van der Wouden, EJ
    Thijs, JC
    Van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (03) : 297 - 302
  • [3] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori (HP).
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    GASTROENTEROLOGY, 1997, 112 (04) : A192 - A192
  • [4] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    GUT, 1997, 41 : A103 - A104
  • [5] Prospective randomized comparisons of ranitidine bismuth citrate (RBC) versus colloidal bismuth subcitrate (Denol)-based triple therapy for the treatment of H-pylori infection.
    Kung, NNS
    Sung, JY
    Yuen, WF
    Li, TH
    Ng, PW
    Lai, WM
    Leung, MF
    GASTROENTEROLOGY, 1998, 114 (04) : A190 - A190
  • [6] A prospective randomized trial of one-week bismuth ranitidine citrate (RBC) triple therapies for H-pylori infection.
    Sung, JJY
    Chan, FKL
    Leung, WK
    Wu, JCY
    Suen, R
    Ling, TKW
    Lee, YT
    Cheng, AFB
    Chung, SCS
    GASTROENTEROLOGY, 1999, 116 (04) : A321 - A321
  • [7] High H-pylori eradication rate with a one week triple regimen containing ranitidine bismuth citrate (RBC)
    Gudjonsson, H
    Bardhan, KD
    Hoie, O
    Kristensen, ES
    Schuetz, E
    KliebeFrisch, C
    Duggan, AE
    GUT, 1997, 41 : A99 - A99
  • [8] Ranitidine bismuth citrate (RBC)-based triple therapies for recurring Helicobacter pylori (Hp) eradication
    Yakovenko, A
    Grigoriev, P
    Yakovenko, E
    Abazova, F
    Poliakov, A
    Agafonova, N
    Pryanishnikova, A
    Chtcherbina, E
    Gulyaev, P
    Gorodinskaya, V
    Avanyan, N
    GUT, 1999, 45 : A117 - A118
  • [9] Efficacy of 1-week ranitidine-bismuth-citrate (RBC)-based triple therapy for eradication of Helicobacter pylori infection
    Savarino, V
    Vigneri, S
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (09) : 1251 - 1251
  • [10] Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with H-pylori infection
    Cestari, R
    Corti, G
    Formenti, A
    Galli, F
    Gatti, M
    Marotta, F
    Milesi, F
    Paterlini, A
    Piubello, W
    Ravelli, P
    Tonini, G
    Ubiali, P
    Valenghi, D
    Fina, P
    Olivieri, A
    Tosatto, R
    GUT, 1998, 43 : A83 - A84
12345